Oncolin Therapeutics, Inc. Provides a Company Overview

HOUSTON--(BUSINESS WIRE)--Oncolin Therapeutics, Inc. (OTCBB:OCOL) (Oncolin) recently completed a name change from Edgeline Holdings, Inc. and began trading under its new symbol (OTCBB:OCOL) on March 24, 2008. Oncolin is now a biotherapeutic company focused on developing drugs which interfere with the key mechanisms of cancer tumor development. The company is developing a lead drug for brain cancer, ONC-127, which is currently in preclinical development.